Picture loading failed.

Anti-MMP9 therapeutic antibody (Pre-made Andecaliximab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Andecaliximab (INN; development code GS-5745) is an experimental humanized monoclonal antibody designed for the treatment of cancer and inflammatory diseases.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-024-1mg 1mg 3090
GMP-Bios-ab-024-10mg 10mg 21890
GMP-Bios-ab-024-100mg 100mg 148000
GMP-Bios-ab-024-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-MMP9 therapeutic antibody (Pre-made Andecaliximab biosimilar,Whole mAb)
INN Name Andecaliximab
FormatWhole mAb
DerivationChimeric (Mouse/Human)
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusDiscontinued
100% SI Structure5th9:HL:IM:JN
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2016
Year Recommended2017
CompaniesGilead Sciences
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedChronic obstructive pulmonary disease;Crohn's disease;Cystic fibrosis;Rheumatoid arthritis;Ulcerative colitis;Gastric cancer;Solid tumours;Glioblastoma
Development Techna